TheraJects transdermal technology addresses these areas by enabling:
- Pain-free, minimally invasive interstitial fluid access in the skin -- avoiding GI
tract
- Tailored release profile -- rapid onset and/or continuous delivery
- Reduced drug dose and/or extended activity due to enhanced bioavailability
- Improved storage and transportation stability
VaxMAT and DrugMATcan help solve several important problems
in the delivery of drugs and vaccines by dramatically overcoming
the limits of conventional transdermal and hypodermic drug
delivery. Conventional patch systems cannot deliver molecules
larger than 500 Daltons (atomic mass units), and therefore
cannot deliver large molecules, proteins, and vaccines. DrugMAT
and VaxMAT have no molecular weight limits and, therefore, can
transdermally delivery large molecules such as proteins,
vaccines, and genetic materials. DrugMAT and VaxMAT will be
developed for broad use because of their advantages in flexible
release profile, dose, safety, efficiency, patient comfort, ease of
use, and cost of production. With TheraJectMAT and VaxMAT,
TheraJect has achieved patent protected technological
breakthroughs that should enable safe, effective, and economical
transdermal delivery of large molecules and small molecules
such as pain-related drugs unsuitable for currently available
transdermal systems.
in the delivery of drugs and vaccines by dramatically overcoming
the limits of conventional transdermal and hypodermic drug
delivery. Conventional patch systems cannot deliver molecules
larger than 500 Daltons (atomic mass units), and therefore
cannot deliver large molecules, proteins, and vaccines. DrugMAT
and VaxMAT have no molecular weight limits and, therefore, can
transdermally delivery large molecules such as proteins,
vaccines, and genetic materials. DrugMAT and VaxMAT will be
developed for broad use because of their advantages in flexible
release profile, dose, safety, efficiency, patient comfort, ease of
use, and cost of production. With TheraJectMAT and VaxMAT,
TheraJect has achieved patent protected technological
breakthroughs that should enable safe, effective, and economical
transdermal delivery of large molecules and small molecules
such as pain-related drugs unsuitable for currently available
transdermal systems.